This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Microtubule- associated protein- τ (MAPT; tau; FTDP- 17); presenilin 1 (PSEN1; PS1)	<p>Mouse studies suggest that tau-targeted immunotherapy could help treat cognitive decline in AD. In a mouse model of tau tangle development, expression of mutant PS1 plus all six human tau isoforms led to faster onset and more rapid progression of tau aggregate-induced cognitive decline than expression of only the six human tau isoforms. Also in the mouse model, immunization with a tau peptide led to less tau aggregation in the brain and better memory in behavioral tests than no immunization. Ongoing work includes testing other tau-targeted antibodies and peptides in the mouse models.</p> <p>ReS19-T, a small molecule against an undisclosed target that prevents neurotoxicity associated with tau from reMYND N.V., is in preclinical testing to treat AD.</p> <p>SciBX 3(48); doi:10.1038/scibx.2010.1451 Published online Dec. 16, 2010</p>	Patented by the New York University School of Medicine; available for licensing or partnering	<p>Boutajangout, A. <i>et al. J. Neurosci.</i>; published online Dec. 8, 2010; doi:10.1523/JNEUROSCI.4363-10.2010</p> <p>Contact: Einar M. Sigurdsson, New York University School of Medicine, New York, N.Y. e-mail: einar.sigurdsson@nyumc.org</p>